Fig. 1: High-level expression and characterization of S-Trimer. | Nature Communications

Fig. 1: High-level expression and characterization of S-Trimer.

From: S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Fig. 1: High-level expression and characterization of S-Trimer.The alternative text for this image may have been generated using AI.

a Schematic representations of full-length SARS-CoV-2 Spike (S) protein and the ectodomain of wild-type SARS-CoV-2 S protein-Trimer-Tag fusion protein (S-Trimer). b Schematic 2-D illustration of S-Trimer with homotrimeric Spike protein in the prefusion conformation. c Reducing SDS-PAGE analysis with Coomassie Blue staining of high-level expression of S-Trimer as a secreted protein from CHO cells in a 15L bioreactor Fed-batch serum-free culture over 11 days (10 µL of cleared media were loaded for each sample) along with a purified standard (Std). d S-Trimer is a disulfide bond-linked homotrimer as analyzed by SDS-PAGE with Coomassie Blue staining under non-reducing (-ME) and reducing (+ME) conditions. S-Trimer was shown to be partially cleaved at S1/S2 junction as indicated. e S-Trimer is heavily N-glycosylated. Analysis of S-Trimer before and after deglycosylation with PNGase F (-N) and PNGase F & Endo-O (-O) by SDS-PAGE with Coomassie Blue staining under reducing (+ME) condition. f SEC-HPLC analysis of the purity of S-Trimer with an MW of approximately 700 Kda, and a small fraction of cleaved S1 was shown detached from S-Trimer as indicated. g Determination of the binding affinity between S-Trimer and human ACE2-Fc by ForteBio BioLayer interferometry. All of the above results are representatives of at least three independent experiments.

Back to article page